These data reflects the inadequate clinical practice with regard to detecting cases of AATD in an at-risk group such as COPD patients and does not adhere to CPG recommendations, which calls for determining AAT levels in blood for all patients with a COPD diagnosis [1–4]. This evidence concerns the gene SERPINA1 and chronic obstructive pulmonary disease.